Current Reviews in Clinical and Experimental Pharmacology最新文献

{"title":"Cannabidiol-Loaded Smart Hydrogels for Advanced Wound Healing: Drug Delivery Innovations and Therapeutic Perspectives.","authors":"Ayushi Bhandari, Shikha Baghel Chauhan, Indu Singh, Chirag Jain","doi":"10.2174/0127724328453813260323115317","DOIUrl":"https://doi.org/10.2174/0127724328453813260323115317","url":null,"abstract":"<p><p>Chronic wounds are a leading healthcare burden worldwide, fueled by intricate pathophysiology and the inadequacy of standard therapies. The present review critically discusses the novel paradigm of incorporating cannabidiol (CBD), a phytocannabinoid with significant anti-inflammatory, antioxidant, antimicrobial, and pro-regenerative capacities, into advanced smart hydrogel platforms for better wound healing and tissue regeneration. We summarize the strong rationale for CBD, focusing on its multimodal pharmacological effects on central pathways (e.g., proinflammatory cytokines, oxidative stress, fibroblast activity, angiogenesis, endocannabinoid system) and reconciling its inherent delivery issues (poor solubility, instability, pharmacokinetics). The review comprehensively addresses the engineering of stimulus-responsive hydrogels (pH-, temperature-, enzyme-, redox-sensitive) to surmount these challenges. Material properties of key interest-biocompatibility, biodegradation tuneability, mechanical cues emulating ECM, and microenvironment control-are addressed together with innovative crosslinking mechanisms (dynamic covalent bonds, supramolecular interactions) as well as state-of-the-art fabrication techniques (3D/4D bioprinting, electrospinning, microfluidics). We have outlined the mechanisms of controlled release of CBD by wound-specific cues and investigated the synergistic interaction between CBD delivery dynamics and hydrogel characteristics in regulating key cellular events (macrophage polarization, re-epithelialization, ECM remodeling). Preclinical proof of principle for CBD-hydrogel therapeutic utility in various wound models (diabetic, infected, burn) is assessed, with discussion of the landscape of clinical translation, regulatory avenues, and ongoing challenges (scalability, standardization, long-term safety). Lastly, the review points to future frontiers such as closed-loop \"sense-and-respond\" systems, AI-assisted design, personalized point-of-- care manufacturing, and combinatorial strategies. We conclude that smart CBD-loaded hydrogels hold a promising approach to meeting unmet needs in treating chronic wounds by delivering localized, sustained, and physiologically responsive release to realize CBD's full therapeutic potential for regenerative medicine.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective Effect of Apelin and Apela: The Receptor and Signaling Mechanism.","authors":"Leonid N Maslov, Sergey V Popov, Alexandr V, Alisa S Slidnevskaya, Natalia V Naryzhnaya, Alexander S Gorbunov, Mikhail Kilin, Viacheslav N Azev, Feng Fu, Philipp A Ilinykh, Huijie Ma","doi":"10.2174/0127724328447640260323172816","DOIUrl":"https://doi.org/10.2174/0127724328447640260323172816","url":null,"abstract":"<p><p>The development of new approaches for the treatment of acute myocardial infarction (AMI) remains a major goal of modern medicine. The objective of the review is an analysis of data on the signaling mechanism of apelin-induced cardiac tolerance to ischemia/reperfusion (I/R). There is evidence that apelin and apela act as autocrine and paracrine factors rather than circulating hormones with a short in vivo half-life. Apelin and apela increase cardiac tolerance to I/R. These peptides decrease infarct size and improve recovery of ventricular function in reperfusion. Apelin activates three signaling pathways: Gi/o protein dependent, Gq/11 protein dependent, and β-arrestin mediated. All three pathways could be involved in the cardioprotective effect of apelin. The following enzymes mediate apelin-induced cardioprotection: NO-synthase (NOS), epidermal growth receptor kinase, phospholipase C (PLC), protein kinase C (PKC), phosphoinositide 3-kinases (PI3K), Src kinase, Akt kinase (Akt), AMP-activated protein kinase (AMPK), guanylyl cyclase (GC), and extracellular signal-regulated kinase (ERK). ATP-sensitive K+ channel (KATP channel) opening and mitochondrial permeability transition (MPT) pore closure may also be involved in apelin-induced cardiac tolerance to I/R. Apelin and apela molecules may form the basis for the creation of new drugs for the treatment of AMI.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabidiol as a Modulator of the Gut-Liver Axis: Clinical and Pharmacological Insights into Hepatic and Metabolic Disorder Therapies.","authors":"Shikha Baghel Chauhan, Indu Singh, Khushi Dahiya, Chirag Jain","doi":"10.2174/0127724328431124260314092422","DOIUrl":"https://doi.org/10.2174/0127724328431124260314092422","url":null,"abstract":"<p><p>A non-intoxicating substance produced from Cannabis sativa, cannabidiol (CBD) has shown promise as a treatment for metabolic and hepatic diseases, primarily due to its capacity to alter the gut-liver axis. A vital bidirectional communication pathway, the gut-liver axis is where substances produced from the liver affect gut homeostasis and gut-derived microbial products and metabolites influence liver health. Conditions including alcoholic liver disease (ALD), metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD) are mostly caused by dysregulation of this axis. According to preclinical research, CBD has hepatopro-tective benefits via improving the integrity of the gut barrier, decreasing intestinal permea-bility, altering the gut microbiota, and suppressing inflammatory signaling pathways such NF-κB and NLRP3 inflammasome activation. Furthermore, CBD improves insulin sensitivi-ty and lowers hepatic steatosis via modifying lipid and glucose metabolism via the PPARγ and CB1/CB2 receptor pathways. Its antioxidant qualities also help to lessen cellular dam-age and oxidative stress in hepatic tissues. Despite these encouraging results, there is still inconsistency in the clinical data because of variations in dosage, formulation, administra-tion method, and patient-specific variables including liver function and microbiota makeup. Furthermore, broad therapeutic usage is restricted by issues with hepatic metabolism, pos-sible drug-drug interactions, and regulatory obstacles. This review highlights information gaps, critically assesses the available preclinical and clinical evidence, and investigates the mechanisms underlying CBD's impact on the gut-liver axis. Additionally, it identifies po-tential avenues for future optimization of CBD-based therapies targeting liver and metabol-ic illnesses through personalized medicine, sophisticated delivery methods, and standard-ized clinical trial procedures.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Pharmacological Therapies in the Management of Hyperlipidemia.","authors":"Nikhil Sharma, Supriya Roy","doi":"10.2174/0127724328440604260225063619","DOIUrl":"https://doi.org/10.2174/0127724328440604260225063619","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperlipidemia remains a major contributor to cardiovascular diseases, with statins and fibrates being the most prescribed treatments. However, these therapies are associated with significant adverse effects. Statin-associated muscle symptoms affect 5-20% of patients, ranging from mild myalgia to severe rhabdomyolysis, and some patients do not achieve optimal lipid control even at high doses. Fibrates, while used as adjuncts to statins, have limited cardiovascular benefits when used as monotherapy and carry risks of myopathy, liver/kidney dysfunction, limiting their clinical utility and signifying the unmet clinical needs. The review aims to provide an update on the clinical efficacy, safety profiles, and mechanistic foundations of emerging lipidlowering therapies as adjuncts for patients who exhibit statin intolerance or an ineffective response to conventional pharmacotherapeutics.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted using various databases to search relevant preclinical and clinical studies published up to 2025 on novel lipid-lowering drugs, including PCK9 inhibitors, bempedoic acid, siRNA-based therapies, and phototherapeutics.</p><p><strong>Results: </strong>PCSK9 inhibitors have demonstrated significant efficacy through the enhancement of LDL receptor activity and subsequent cholesterol clearance. Bempedoic acid offers an alternative mechanism via ATP citrate lyase inhibition, accomplishing prominent lipid reduction without musclerelated adverse events. Concurrently, siRNA technologies targeting apolipoprotein C3 (apoC-III) and PCSK9 demonstrate promising efficacy in addressing both hypertriglyceridemia and hypercholesterolemia with prolonged dosing intervals. Phytotherapeutic agents, including Ruta chalepensis, wheat β-glucan, quercetin, and Liubao tea extract, exert multifaceted effects through antiinflammatory mechanisms, regulation of lipid metabolic pathways, and modulation of gut microbiota composition, representing an integrative approach to dyslipidemia management.</p><p><strong>Discussion: </strong>These new treatments provide mechanistically distinct alternatives to statins and fibrates that improve lipid control in patients with intolerance or suboptimal response. Nevertheless, robust long-term outcome trials are required to validate cardiovascular benefits and to guide individualized treatment strategies.</p><p><strong>Conclusion: </strong>These therapeutic innovations represent a paradigm shift in hyperlipidemia management, providing mechanistically diverse and efficacious alternatives for patients with statin intolerance or suboptimal response to conventional therapies, ultimately enhancing lipid control and cardiovascular outcomes.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data-Driven Toxicity Prediction: Advances in Machine Learning, Deep Learning, and Predictive Tools - A Systematic Review.","authors":"Hany Akeel Al-Hussaniy, Kadhim Adnan Ali, Samer Tareq Jasim, Ali Al-Samydai","doi":"10.2174/0127724328441651260211220550","DOIUrl":"https://doi.org/10.2174/0127724328441651260211220550","url":null,"abstract":"<p><strong>Introduction/objective: </strong>High rate of attrition still inhibits drug discovery and development, with toxicity accounting for one of the primary causes of failure in preclinical and clinical development. This review summarizes Machine Learning (ML), Deep Learning (DL), and emerging post-deep learning strategies in drug discovery and environmental safety.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a systematic search was conducted across PubMed, Web of Science, Scopus, and ScienceDirect for the years 2015-2025, yielding 1,020 articles. Additional records were obtained from Google Scholar and the reference lists of about 60 articles. The studies were included when they used ML/DL to predict toxicity, provided quantitative measures of performance (e.g., accuracy, AUC, F1-score), or when they described the predictive tools and platforms. Eligibility criteria were: the study was entirely experimental toxicology with no computational modeling of the study, lacked an adequate description of the methodology, or was in a non- English language. The last study count of the paper is 50 articles.</p><p><strong>Results: </strong>DL models like convolutional and graph neural networks are more effective in cases when the size of the datasets is large. Recent methods that address the problem of data scarcity are property augmentation, transfer learning, and semi-supervised learning. A number of web-based applications (e.g., ADMETlab 3.0, admetSAR 3.0, ProTox 3.0) have been published that allow using multi-endpoint prediction with different measures of accuracy and interpretability.</p><p><strong>Discussion: </strong>Traditional ML methods, particularly support vector machines and random forests, remain valuable for smaller datasets due to their robustness and interpretability. However, the adoption of deep learning architectures, such as convolutional and graph neural networks, has markedly improved predictive accuracy when applied to large and complex datasets.</p><p><strong>Conclusions: </strong>Data-driven methods have significantly advanced toxicity prediction, offering faster and more cost-effective tools compared with traditional assays. However, the field still faces challenges related to limited datasets, variable data quality, and a lack of mechanistic interpretability.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolving Pain: Preclinical Insights into the Analgesic Mechanisms of RvD1.","authors":"Geovana Martelossi-Cebinelli, Tiago H Zaninelli, Rubia Casagrande, Sergio M Borghi, Waldiceu A Verri","doi":"10.2174/0127724328436999251223054038","DOIUrl":"10.2174/0127724328436999251223054038","url":null,"abstract":"<p><p>Pain is a protective mechanism of the body that is intensified during inflammatory processes through the sensitization of nociceptive neurons. Although current drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and opioids, are effective, their side effects reinforce the search for safer alternatives. In this context, studies investigating the analgesic effects of specialized pro-resolving mediators (SPMs), derived from polyunsaturated fatty acids, stand out. Resolvin D1 (RvD1), derived from the omega-3 fatty acid docosahexaenoic acid, acts in a multimodal manner to modulate pain and inflammation by regulating immunological, neuronal, and glial responses. Thus, RvD1 is a promising molecule for resolving inflammatory and painful processes. Herein, we address the main analgesic mechanisms of RvD1 in different preclinical models.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Significance of Model-Based Strategies in Drug Development throughout the Lifecycle and Regulatory Decision-Making.","authors":"Maitry Suthar, Neha Dandekar, Dipti Patel, Drashti Shah","doi":"10.2174/0127724328406757251204044645","DOIUrl":"https://doi.org/10.2174/0127724328406757251204044645","url":null,"abstract":"<p><strong>Introduction: </strong>Model-informed drug development (MIDD) is a regulatory-endorsed approach that streamlines drug discovery, development, and approval. Actively promoted by the U.S. Food and Drug Administration (FDA), it integrates quantitative modelling to support decision-making across drugs, generics, and biologics.</p><p><strong>Objectives: </strong>This study aims to highlight the applications, benefits, and future perspectives of MIDD in optimizing clinical trial design, supporting regulatory review, advancing biopharmaceutics, and enabling innovation in emerging therapeutic areas.</p><p><strong>Methods: </strong>Current applications of MIDD were evaluated, focusing on its role in new drug development, generic drug approval, biopharmaceutics, and early exploration in cell and gene therapy. The study emphasizes computational modelling, dose optimization, clinical trial refinement, and postapproval lifecycle management strategies.</p><p><strong>Results: </strong>MIDD has demonstrated considerable impact in optimizing dose selection, refining trial design, and addressing regulatory concerns regarding efficacy and safety. In the field of biopharmaceutics, computational modelling has guided formulation development and facilitated subsequent in vivo studies. In genetics, mathematical modelling has enabled efficient development and approval of complex formulations, reducing both time and cost. MIDD shows strong potential for quantitatively analysing biological activity, pharmacodynamics, transgene expression, immune responses, safety, and therapeutic effectiveness.</p><p><strong>Conclusion: </strong>MIDD is a transformative approach in drug development, offering robust tools for decision- making and regulatory assessment. Its broader implications across therapeutic domains are expected to enhance innovation, improve patient outcomes, and reduce development costs. Future advancements, particularly in cell and gene therapy, will further expand its role as a cornerstone of drug development.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daprodustat vs Recombinant Human Erythropoietin for Anemia and Cardiovascular Safety in Dialysis-Dependent and Non-Dialysis-Dependent CKD Patients - A Systematic Review and Meta-analysis.","authors":"Hara Prasad Mishra, Rachna Gupta, Shubhima Grover, Lalit K Gupta","doi":"10.2174/0127724328377421251117050736","DOIUrl":"https://doi.org/10.2174/0127724328377421251117050736","url":null,"abstract":"<p><strong>Background: </strong>Anemia is a prevalent complication in chronic kidney disease (CKD) that remains challenging to manage effectively. Daprodustat was recently approved for anemia in CKD. This meta-analysis aims to provide evidence-based insights for the clinical use of daprodustat in CKD-related anemia.</p><p><strong>Method: </strong>A systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines, with searches conducted in databases such as PubMed and ClinicalTrials.gov, encompassing studies published up to August 30, 2024. Data from 12 randomized controlled trials involving 9,278 CKD patients (both dialysis-dependent (DD) and non-dialysis-dependent (NDD)) were analyzed.</p><p><strong>Results: </strong>Daprodustat significantly increased hemoglobin (Hb) levels compared to placebo in both NDD (MD = 1.92, 95% CI [0.67, 3.02], p = 0.001) and DD (MD = 1.72, 95% CI [0.34, 3.65], p = 0.01) patients. However, no significant difference in Hb levels was observed between daprodustat and recombinant human erythropoietin (rhEPO) (MD = 0.05, 95% CI [-0.10, 0.21], p = 0.50). Daprodustat improved iron metabolism by significantly lowering hepcidin and increasing total ironbinding capacity (TIBC) compared to rhEPO. Cardiovascular safety analysis showed no significant difference in major adverse cardiovascular events (MACE) between daprodustat and rhEPO (RR = 1.02, 95% CI [0.92, 1.14], p = 0.83), though a significant reduction in MACE incidence was observed in DD patients (RR = 0.98, 95% CI [0.87, 1.15], p = 0.02). Serious adverse events were significantly lower with daprodustat compared to rhEPO (RR = 0.82, 95% CI [0.66, 0.84], p = 0.02 in DD; RR = 0.61, 95% CI [0.48, 0.78], p = 0.008 in NDD patients).</p><p><strong>Conclusion: </strong>Daprodustat offers a promising alternative to traditional anemia treatments in CKD, with efficacy comparable to rhEPO and a favorable cardiovascular safety profile, which marks its potential as a valuable therapeutic option.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan","doi":"10.2174/0127724328356429250315163111","DOIUrl":"10.2174/0127724328356429250315163111","url":null,"abstract":"<p><strong>Introduction: </strong>Statin-induced myopathy (SIM) is a prevalent adverse event impacting treatment adherence. Despite extensive exploration of single nucleotide polymorphisms (SNPs), conflicting evidence obscures their role in SIM incidence, prompting this network meta-analysis.</p><p><strong>Methods: </strong>Observational studies meeting eligibility criteria (patients on any statin with reported SNPs and SIM details) were systematically reviewed. Severe SIM was defined as creatine kinase elevations exceeding 10 times the upper limit of normal. Mixed treatment comparison pooled estimates were generated from direct and indirect pooled estimates, represented by odds ratios (OR) with 95% confidence intervals (CI), and validated via bootstrap analysis.</p><p><strong>Results: </strong>Thirty-four studies (26,152 participants) examining genotypes spanning drug transporters, metabolizing enzymes, reactive oxygen species production, and myopathy-related genes were analyzed. Significant associations were observed with drug transporters (OR: 1.4; 95% CI: 1.04, 1.5). Notably, solute carrier organic anion transporter 1B1 (SLCO1B1) (rs4149056) exhibited a moderate association with SIM (OR: 2.1; 95% CI: 1.7, 2.6), validated by bootstrap analysis (OR: 2.1; 95% CI: 1.7, 2.8). Similar associations were found for severe SIM with SLCO1B1 (rs4149056) (OR: 3.8; 95% CI: 1.4, 10.4) and ATP Binding Cassette Subfamily B Member 1 (ABCB1) (rs2373588) (OR: 2.8; 95% CI: 1.4, 5.4). Intraclass differences in genetic predictor risks were noted among statins.</p><p><strong>Conclusion: </strong>Our meta-analysis underscores the significant association of SLCO1B1 with SIM, supporting its clinical utility. Further research is warranted to clarify additional genetic predictors. These findings endorse current guidelines advocating for SLCO1B1 genotyping in statin therapy decisions.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"75-91"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Reviews in Clinical and Experimental Pharmacology (CRCEP)-Preface-2026.","authors":"Arduino A Mangoni","doi":"10.2174/0127724328452067251106080641","DOIUrl":"10.2174/0127724328452067251106080641","url":null,"abstract":"","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"iv"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}